{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:30:15Z","timestamp":1792870215213,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007195","name":"University of Naples Federico II","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejim.2024.05.011","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:11:32Z","timestamp":1715991092000},"page":"28-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-4657","authenticated-orcid":false,"given":"Gilda","family":"Varricchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-0167","authenticated-orcid":false,"given":"Remo","family":"Poto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.05.011_bib0001","unstructured":"(GOLD), G.I.f.C.O.L.D., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report. https:\/\/goldcopd.org\/2024-gold-report\/. 2024."},{"issue":"11","key":"10.1016\/j.ejim.2024.05.011_bib0002","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","article-title":"An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal","volume":"204","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ejim.2024.05.011_bib0003","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.ejim.2024.05.011_bib0004","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.202009-3448OC","article-title":"Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis","volume":"203","author":"Wang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.011_bib0005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ejim.2024.05.011_bib0006","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/cells11101720","article-title":"Angiogenesis, lymphangiogenesis, and inflammation in chronic obstructive pulmonary disease (COPD): few certainties and many outstanding questions","volume":"11","author":"Poto","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.ejim.2024.05.011_bib0007","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S2213-2600(23)00261-8","article-title":"COPD and multimorbidity: recognising and addressing a syndemic occurrence","volume":"11","author":"Fabbri","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.011_bib0008","doi-asserted-by":"crossref","first-page":"e174786","DOI":"10.1172\/jci.insight.174786","article-title":"Activator protein transcription factors coordinate human IL-33 expression from noncanonical promoters in chronic airway disease","volume":"9","author":"Raphael","year":"2024","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.011_bib0009","doi-asserted-by":"crossref","first-page":"1900110","DOI":"10.1183\/13993003.00110-2019","article-title":"Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue","volume":"55","author":"Jogdand","year":"2020","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ejim.2024.05.011_bib0010","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.rmed.2005.11.009","article-title":"Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction","volume":"100","author":"Calabrese","year":"2006","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2024.05.011_bib0011","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.011_bib0012","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.011_bib0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.011_bib0014","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/all.14016","article-title":"Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma","volume":"75","author":"George","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.ejim.2024.05.011_bib0015","unstructured":"(GINA), G.I.f.A., Global strategy for asthma management and prevention. www.ginasthma.org. 2024."},{"issue":"4","key":"10.1016\/j.ejim.2024.05.011_bib0016","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial Alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2024.05.011_bib0017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-med-060622-101239","article-title":"Precision approaches to chronic obstructive pulmonary disease management","volume":"75","author":"Moll","year":"2024","journal-title":"Annu Rev Med"},{"issue":"168","key":"10.1016\/j.ejim.2024.05.011_bib0018","doi-asserted-by":"crossref","first-page":"220193","DOI":"10.1183\/16000617.0193-2022","article-title":"Cytokine-targeted therapies for asthma and COPD","volume":"32","author":"Schleich","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"167","key":"10.1016\/j.ejim.2024.05.011_bib0019","doi-asserted-by":"crossref","first-page":"220144","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"12","key":"10.1016\/j.ejim.2024.05.011_bib0020","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.011_bib0021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaci.2023.10.022","article-title":"Dupilumab in type 2 airway inflammation-a step forward in targeted therapy for COPD","volume":"153","author":"Tan","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.011_bib0022","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"25","key":"10.1016\/j.ejim.2024.05.011_bib0023","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejim.2024.05.011_bib0024","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejim.2024.05.011_bib0025","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejim.2024.05.011_bib0026","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2024.05.011_bib0027","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.011_bib0028","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.011_bib0029","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.05.011_bib0030","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fimmu.2018.01595","article-title":"Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.011_bib0031","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","article-title":"Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease","volume":"181","author":"Ying","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ejim.2024.05.011_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2024.02.020","article-title":"TSLP is localized in and released from human lung macrophages activated by T2-high and T2-low stimuli: relevance in asthma and COPD","author":"Cane","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"11","key":"10.1016\/j.ejim.2024.05.011_bib0033","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524002152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524002152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T21:41:12Z","timestamp":1719783672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524002152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"alternative-id":["S0953620524002152"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.05.011","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}